- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00301288
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL).
Patients with aggressive Non-Hodgkin-lymphoma treated at first diagnosis with chemotherapy alone or combined chemo-radiotherapy can achieve high response rates. However, patients with relapsed lymphoma still have a poor prognosis. High dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the treatment of choice for these patients. An ASCT allows patients to receive much higher doses of chemotherapy than usual, to improve the chances of curing the disease. The high-dose of chemotherapy destroys the cells in the patients bone marrow and then the patients own cells from either the bone marrow or peripheral blood are used to rescue the patient from intensive treatment. High-dose chemotherapy with autologous stem cell (either bone marrow or peripheral blood) transplantation is used in the treatment of Intermediate/High grade NHL with poor risk disease and in second remission at the Royal Marsden Hospital.
The purpose of the present analysis is to determine independent prognostic factors correlated with the long-term outcome of patients with NHL who received an ASCT between January 1991 and June 2005. Accrual of eligible patients currently under follow-up will be performed in clinic at the time of next appointment. All patients accrued will give informed consent to participate in the study for retrospective case note review, after discussion with a study investigator and after receiving a study information sheet. The results of the analysis will be published in a peer-reviewed medical journal. This will include patients treated at the royal Marsden Hospital only.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Contacts and Locations
Study Locations
-
-
Surrey
-
Sutton, Surrey, United Kingdom, SM2 5PT
- Royal Marsden NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- a) Age over 18 b) Patients with Non-Hodgkin's Lymphoma who have received an autologous stem cell transplant in the past.
c) Informed written consent
Exclusion Criteria:
- a) Medical or psychiatric conditions that compromise the patient's ability to give informed consent b) HIV positive or AIDS related lymphoma
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Investigators
- Principal Investigator: David Cunningham, FRCP, Royal Marsden NHS Foundation Trust
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2657
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkins Lymphoma
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineRecruitingHodgkins Lymphoma | Non Hodgkins LymphomaUnited States
-
Spectrum Pharmaceuticals, IncCompletedNon-Hodgkins Lymphoma | Tumors | Hodgkins DiseaseUnited States, Canada
-
Children's Hospital Los AngelesCompletedHodgkins Lymphoma | Non-hodgkins LymphomaUnited States
-
New York Medical CollegeJohns Hopkins University; M.D. Anderson Cancer Center; Baylor College of Medicine and other collaboratorsCompletedNon-Hodgkins Lymphoma | Lymphoproliferative Disorder | Hodgkins LymphomaUnited States
-
Weill Medical College of Cornell UniversityCompletedHodgkins Disease | Lymphoma, Non-HodgkinsUnited States
-
SCRI Development Innovations, LLCBiogenCompleted
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); Pfizer; Millennium Pharmaceuticals, Inc.CompletedNon-Hodgkins LymphomaUnited States
-
Maisonneuve-Rosemont HospitalBayerUnknownNon-Hodgkins LymphomaCanada
-
National Cancer Institute (NCI)TerminatedLeukemia | Multiple Myeloma | MDS | Non-Hodgkins Lymphoma | Hodgkins LymphomaUnited States
-
University of NebraskaSchering-PloughCompletedNon-Hodgkins LymphomaUnited States
Clinical Trials on Autologous stem cell transplant
-
Royal Marsden NHS Foundation TrustCompleted
-
European Society for Blood and Marrow TransplantationThe Broad FoundationTerminatedCrohn DiseaseUnited Kingdom, Italy, Switzerland, Belgium, Canada, France, Spain
-
Centro de Hematología y Medicina InternaEnrolling by invitation
-
Mundipharma-EDO GmbHTerminatedMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma ProgressionSwitzerland, United States, Norway
-
Northwestern UniversityTerminated
-
Azienda Ospedaliera San Giovanni BattistaCompleted
-
Gary A Levy, O. Ont. MD. FRCP AGAFOttawa Hospital Research InstituteCompletedComplication of Transplanted Organ, NosCanada
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingPlasma Cell MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Terminated